Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

• Conditions: Glioblastoma Multiforme; Angiogenesis

• Registration Number: NCT03225963
• Lead Sponsor: Taichung Veterans General Hospital

Brief Summary

Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Detailed Description

Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.

Study Timeline

• Study Start: 2015-08-01
• Status Verified: 2017-07
• Study First Submitted: 2017-07-19
• Study First Submitted QC: 2017-07-19
• Last Update Submitted: 2017-07-20
• Study First Posted: 2017-07-21
• Last Update Posted: 2017-07-24
• Primary Completion: 2018-07-31
• Study Completion: 2018-07-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Age older than 20 year old.
• Glioblastoma patients who will receive chemoradiation treatment.

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response of bevacizumab therapy.	3 months after bevacizumab therapy	Base on the image after bevacizumab therapy (after recurrence)

Trial Locations

Locations (1)

Taichung Veterans General Hospital; 🇨🇳 Taichung, Taiwan